Developing Cardio-Oncology Programs in the New Era: Beyond Ventricular Dysfunction Due to Cancer Treatments.

Autor: Pons-Riverola A; Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.; Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.; Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain., Morillas H; Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.; Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.; Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain., Berdejo J; Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.; Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.; Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain., Pernas S; Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.; Medical Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain., Pomares H; Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.; Clinical Haematology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain., Asiain L; Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.; Radiation Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain., Garay A; Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.; Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.; Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain., Fernandez-Ortega A; Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.; Medical Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain., Oliveira AC; Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.; Clinical Haematology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.; Haematopoietic and Lymphoid Tumours Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain., Martínez E; Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.; Radiation Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.; Radiobiology and Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain., Jiménez-Marrero S; Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.; Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.; Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain., Pina E; Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.; Thrombosis and Haemostasis Unit, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain., Fort E; Pharmacy Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain., Ramos R; Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.; Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.; Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain., Alcoberro L; Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.; Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain., Hidalgo E; Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain., Antonio-Rebollo M; Oncogeriatrics Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain., Alcober L; Primary Care Service Delta del Llobregat and IDIAP, Catalan Health Service, 08007 Barcelona, Spain., Enjuanes Grau C; Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.; Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain., Comín-Colet J; Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.; Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain., Moliner P; Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.; Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.; Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2023 Dec 18; Vol. 15 (24). Date of Electronic Publication: 2023 Dec 18.
DOI: 10.3390/cancers15245885
Abstrakt: Cardiovascular disease is a common problem in cancer patients that is becoming more widely recognized. This may be a consequence of prior cardiovascular risk factors but could also be secondary to the anticancer treatments. With the goal of offering a multidisciplinary approach to guaranteeing optimal cancer therapy and the early detection of related cardiac diseases, and in light of the recent ESC Cardio-Oncology Guideline recommendations, we developed a Cardio-Oncology unit devoted to the prevention and management of these specific complications. This document brings together important aspects to consider for the development and organization of a Cardio-Oncology program through our own experience and the current evidence.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje